Anacor Pharmaceuticals (NASDAQ:ANAC)On Monday July 13, 2015 shares of Anacor went up 55%, closing around $131.93 per share after the company announced positive phase 3 results in patients who have atopic dermatitis. There were two phase 3 trials that were testing Anacor’s drug, Crisaborole, for these patients with atopic dermatitis — also known as Eczema. The company wanted to see […]
Related ALXNUS Stock Futures Drop Ahead Of Economic DataStrensiq Receives Marketing Approval in Japan for Treatment of Patients with HypophosphatasiaBy and large, the number of shares short in the leading biotech and emerging pharmaceutical stocks shrank between the June 15 and June 30 settlement dates.The trend was particularly noticeable in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Gilead Sciences, Inc. (NASDAQ: […]
By Ben LevisohnUBS analyst Mathhew Roden and team still like biotech stocks, but think it’s time to get more selective, recommending “high quality risk reward names” like Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX), while downgrading Amgen (AMGN) and Regeneron Pharmaceuticals (REGN). They explain why:
Freya Ingrid Morales/Bloomberg News
Although we still think that biotech will continue to outperform the broader markets […]
Others note continued opportunity in biotech.Robert Christian, who analyzes hedge funds as head of research at K2 Advisors and Franklin Templeton Solutions, said biotech stock-focused managers stand out as one of his favorite strategies among the few dozen he tracks.Christian’s optimism rests on what he called exciting new technologies that justify higher company valuations.”Biotech used to be about making life […]
APActors Robert Downey Jr. and Jeremy Renner ring the opening bell Monday at the New York Stock Exchange. By Caroline ValetkevitchNEW YORK – U.S. stocks ended down Monday, led by losses in biotech shares after disappointing news from several companies including Amgen.The Nasdaq Biotech Index sank 4.1 percent, its biggest daily percentage loss since March 25, while the S&P […]
Source: Amgen, Flickr.The biotech sector is something of a roulette wheel for investors. The chances of being right are typically against you, but if you can land a winner every now and then the rewards can multiply many times over your initial bet.A majority of the biotech sector is comprised of clinical-stage pipelines or developing product portfolios which are still […]
This Weekend my eyes and thoughts curved around the Healthcare sector. I read several interesting articles from the sector, mostly about the biotech’s and new Hepatitis C drugs from Gilead, Sovaldi and Harvoni.Those are very expensive drugs with potential to kill the current medical systems but they also generate tons of cash for their corporate.I also noticed that the Healthcare […]
Disclosure: I own shares of AMGN and GILDBiotechnology stocks have been in a sharp correction this week. The iShares Nasdaq Biotechnology ETF dropped close to one-percent in early Thursday trade, following a 1.89% decline on Wednesday; and the SPDR S&P biotech ETF registered similar losses.Is the correction a buying opportunity or a wake up call?Both.On the one side, the correction […]
It’s been an eventful week on the pipeline front with companies like Biogen (BIIB – Analyst Report), Prothena (PRTA – Snapshot Report) and Vertex (VRTX – Analyst Report) coming out with data. Meanwhile, Gilead (GILD – Analyst Report) was back in the news once again due to its hepatitis C virus (HCV) franchise.Recap of the Week’s Most Important Stories1. Hopes […]
Seymour warned that the fund sat in “overbought territory,” saying that it might soon pull back. Trader Brian Kelly agreed, adding that investors might want to take profits on biotech names next week.Some biotech names may not have exhausted their momentum, trader Guy Adami said. He believes that Celgene could move even higher, adding that Gilead and Amgen may have […]
